Can Paxlovid, Molnupiravir Benefit Hospitalized COVID Patients Too?
During the Omicron BA.2 wave, antivirals molnupiravir and nirmatrelvir-ritonavir (Paxlovid) appeared to have clinical benefit in hospitalized patients with mild-to-moderate COVID-19 who did not require oxygen therapy, a retrospective cohort study from Hong Kong showed. For patients who were treated with the antivirals within 2 days of hospitalization, a 52% and 66% lower risk of […]